XBI ETF holdings (NYSE) | MetaTrader

展开完整图表

概览所有持仓热图

主要持股 Market Value Shares Weight %

APGE Apogee Therapeutics Inc 159.8 M 1.2 M 1.5%

MRNA Moderna Inc 151.6 M 2.2 M 1.4%

TWST Twist Bioscience Corp 151.1 M 1.5 M 1.4%

ORKA Oruka Therapeutics Inc 148.0 M 1.6 M 1.4%

KYMR Kymera Therapeutics Inc 145.9 M 1.3 M 1.4%

VKTX Viking Therapeutics Inc 140.0 M 3.6 M 1.3%

PRAX Praxis Precision Medicines Inc 138.5 M 413.7 K 1.3%

ERAS Erasca Inc 136.4 M 7.4 M 1.3%

RVMD Revolution Medicines Inc 129.3 M 690.5 K 1.2%

RYTM Rhythm Pharmaceuticals Inc 129.0 M 1.2 M 1.2%

CGON CG oncology Inc 128.8 M 1.8 M 1.2%

SLS SELLAS Life Sciences Group Inc 127.7 M 8.7 M 1.2%

PCVX Vaxcyte Inc 127.4 M 2.2 M 1.2%

DNTH Dianthus Therapeutics Inc 127.0 M 1.3 M 1.2%

CYTK Cytokinetics Inc 126.5 M 1.5 M 1.2%

NTRA Natera Inc 124.8 M 459.9 K 1.2%

SRRK Scholar Rock Holding Corp 124.2 M 2.3 M 1.2%

ROIV Roivant Sciences Ltd 124.0 M 3.5 M 1.2%

MIRM Mirum Pharmaceuticals Inc 124.0 M 1.1 M 1.2%

COGT Cogent Biosciences Inc 122.8 M 3.2 M 1.1%

1
2
3
4
5
6
7
8

新闻

Gate 合约股票专区将上线 BOT（机器人策略封闭式基金）等 5 个永续合约交易

Oppenheimer维持Inovio制药"跑赢大盘"评级,关注加速审批途径

William Blair维持Compass Therapeutics增持评级,静待试验数据公布

Oppenheimer三月美股策略：动量策略正当时推荐苹果(AAPL.US)、美铝(AA.US)、贝克休斯(BKR.US)等个股

Citizens重申Ideaya Biosciences股票市场表现优于大盘评级

H.C. Wainwright上调Praxis Precision Medicines股票目标价至1,245美元

Oppenheimer重申Capricor股票"优于大盘"评级，维持54美元目标价

Oppenheimer上调Dianthus Therapeutics股票目标价至125美元，此前为62美元

派博桑德勒将Praxis Precision Medicines股票目标价上调至1,200美元

Roth/MKM 对 Arcturus Therapeutics 股票启动覆盖，给予"买入"评级

野村医疗股票获美银重申"跑赢大盘"评级

Wave Life Sciences股价在Arrowhead数据支持INHBE机制后上涨